Indiana biologics regulations.

Who may administer PRP, exosomes and stem cells in Indiana, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in Indiana?

To legally administer stem cell therapies in Indiana, practitioners must hold valid medical licenses (MD/DO).

Official sources

Indiana compliance guide.

FDA Compliance

Indiana clinics offering biologics must comply with the U.S. Food and Drug Administration (FDA) guidelines for human cells, tissues, and cellular and tissue-based products (HCT/Ps). Key regulations include 21 CFR Part 1271, which outlines standards for the use, storage, and minimal manipulation of HCT/P products. For comprehensive FDA guidance, visit FDA's HCT/P Regulations.

Indiana State Regulations

In Indiana, the Indiana State Department of Health (ISDH) oversees health practices, including regulations for biologics. Clinics should regularly review state-specific guidelines to ensure compliance with Indiana’s requirements. For the most recent updates, see the ISDH website: Indiana State Department of Health. Understanding Indiana’s specific standards will help practitioners ensure accessible and achievable compliance within the state.

Provider Qualifications

To legally administer stem cell therapies in Indiana, practitioners must hold valid medical licenses (MD/DO). Specific certification or training in regenerative medicine is recommended but not always required. Providers can verify qualifications and licensing requirements through the Indiana Professional Licensing Agency (PLA).

Patient Informed Consent

Indiana clinics offering biologic treatments must obtain informed consent from patients, which should include details about the experimental nature of certain stem cell therapies, associated risks and benefits, and any limitations. Consent forms should be clear, outlining the purpose, potential side effects, and the patient’s right to withdraw. Ensuring comprehensive consent protects both the clinic and the patient and aligns with Indiana state standards.

Pre-Treatment and Post-Treatment Protocols

Establishing clear pre- and post-treatment protocols for biologics is essential. These protocols should outline preparatory steps, follow-up care, and any specific recovery requirements. Proper protocols help maintain patient safety and ensure high standards of care.

Standard Operating Procedures (SOPs)

Implementing SOPs is essential for compliance, providing a standardized approach to handling biologic products. SOPs should cover storage, handling, and disposal methods that align with FDA and state guidelines. Consistent SOP adherence minimizes risks and enhances patient safety.

Medical Liability Insurance

Clinics offering biologic treatments are encouraged to obtain comprehensive medical liability insurance. This insurance protects against potential legal claims related to biologic therapies. Providers should check with their insurance carriers to ensure adequate coverage for regenerative medicine practices.

Marketing Compliance

All marketing materials for biologic treatments must comply with Indiana advertising regulations and avoid any claims that may mislead consumers. Marketing should emphasize the experimental nature of certain biologics and avoid unsubstantiated efficacy claims. For FDA advertising guidance, visit FDA Advertising Policies.

This guide is a general summary to help clinics understand compliance requirements for biologics in Indiana. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

Indiana: common questions.

Who can administer stem cells, PRP and exosomes in Indiana?
To legally administer stem cell therapies in Indiana, practitioners must hold valid medical licenses (MD/DO). This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in Indiana?
FDA rules are federal, so they apply in Indiana as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in Indiana?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in Indiana?
Start with the live webinar, then a discovery call and live training. After that we verify your Indiana licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in Indiana? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.